Literature DB >> 31366621

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

Haijiao Zhang1,2, Beth Wilmot3, Daniel Bottomly3, Kim-Hien T Dao2, Emily Stevens4, Christopher A Eide2,5, Vishesh Khanna2,5, Angela Rofelty1,2, Samantha Savage1,2, Anna Reister Schultz1,2, Nicola Long1,2, Libbey White3, Amy Carlos6, Rachel Henson6, Chenwei Lin6, Robert Searles6, Robert H Collins7, Daniel J DeAngelo8, Michael W Deininger9, Tamara Dunn10, Than Hein9, Marlise R Luskin8, Bruno C Medeiros10, Stephen T Oh11, Daniel A Pollyea12, David P Steensma8, Richard M Stone8, Brian J Druker2,5, Shannon K McWeeney3, Julia E Maxson2, Jason R Gotlib10, Jeffrey W Tyner1,2.   

Abstract

Chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (aCML), and myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) are a group of rare and heterogeneous myeloid disorders. There is strong morphologic resemblance among these distinct diagnostic entities as well as a lack of specific molecular markers and limited understanding of disease pathogenesis, which has made diagnosis challenging in certain cases. The treatment has remained empirical, resulting in dismal outcomes. We, therefore, performed whole-exome and RNA sequencing of these rare hematologic malignancies and present the most complete survey of the genomic landscape of these diseases to date. We observed a diversity of combinatorial mutational patterns that generally do not cluster within any one diagnosis. Gene expression analysis reveals enrichment, but not cosegregation, of clinical and genetic disease features with transcriptional clusters. In conclusion, these groups of diseases represent a continuum of related diseases rather than discrete diagnostic entities.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2019        PMID: 31366621      PMCID: PMC6742922          DOI: 10.1182/blood.2019000611

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  40 in total

1.  Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk
Journal:  N Engl J Med       Date:  2016-06-09       Impact factor: 91.245

Review 2.  Genomics of Myeloproliferative Neoplasms.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

3.  An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Authors:  Michael R Savona; Luca Malcovati; Rami Komrokji; Ramon V Tiu; Tariq I Mughal; Attilio Orazi; Jean-Jacques Kiladjian; Eric Padron; Eric Solary; Raoul Tibes; Raphael Itzykson; Mario Cazzola; Ruben Mesa; Jaroslaw Maciejewski; Pierre Fenaux; Guillermo Garcia-Manero; Aaron Gerds; Guillermo Sanz; Charlotte M Niemeyer; Francisco Cervantes; Ulrich Germing; Nicholas C P Cross; Alan F List
Journal:  Blood       Date:  2015-01-26       Impact factor: 22.113

4.  Genomic determinants of chronic myelomonocytic leukemia.

Authors:  B J Patel; B Przychodzen; S Thota; T Radivoyevitch; V Visconte; T Kuzmanovic; M Clemente; C Hirsch; A Morawski; R Souaid; C Saygin; A Nazha; B Demarest; T LaFramboise; H Sakaguchi; S Kojima; H E Carraway; S Ogawa; H Makishima; M A Sekeres; J P Maciejewski
Journal:  Leukemia       Date:  2017-05-30       Impact factor: 11.528

Review 5.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.

Authors:  Cynthia L Fisher; Nicolas Pineault; Christy Brookes; Cheryl D Helgason; Hideaki Ohta; Caroline Bodner; Jay L Hess; R Keith Humphries; Hugh W Brock
Journal:  Blood       Date:  2009-10-27       Impact factor: 22.113

8.  The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

Authors:  Angela G Fleischman; Julia E Maxson; Samuel B Luty; Anupriya Agarwal; Lacey R Royer; Melissa L Abel; Jason D MacManiman; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  Blood       Date:  2013-09-30       Impact factor: 22.113

9.  An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Nicholas C P Cross; Eric Padron; Ramon V Tiu; Michael Savona; Luca Malcovati; Raoul Tibes; Rami S Komrokji; Jean-Jacques Kiladjian; Guillermo Garcia-Manero; Attilio Orazi; Ruben Mesa; Jaroslaw P Maciejewski; Pierre Fenaux; Raphael Itzykson; Ghulam Mufti; Eric Solary; Alan F List
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

10.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors:  Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

View more
  15 in total

1.  Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.

Authors:  Laura Palomo; Manja Meggendorfer; Stephan Hutter; Sven Twardziok; Vera Ademà; Irene Fuhrmann; Francisco Fuster-Tormo; Blanca Xicoy; Lurdes Zamora; Pamela Acha; Cassandra M Kerr; Wolfgang Kern; Jaroslaw P Maciejewski; Francesc Solé; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2020-10-15       Impact factor: 22.113

2.  CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis.

Authors:  Xinmin Zhang; Cristina Ghiuzeli; Erin Jou; Peihong Hsu; Jonathan Kolitz; Judith P Brody
Journal:  Leuk Res Rep       Date:  2022-06-25

3.  Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.

Authors:  Konnie Hebeda; Ludmila Boudova; Christine Beham-Schmid; Attilio Orazi; Hans-Michael Kvasnicka; Umberto Gianelli; Alexandar Tzankov
Journal:  Ann Hematol       Date:  2020-10-31       Impact factor: 3.673

4.  Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia.

Authors:  Franziska C Adam; Jakub Szybinski; Jörg P Halter; Nathan Cantoni; Friedel Wenzel; Katharina Leonards; Sime Brkic; Jakob R Passweg; Ivo Touw; Julia E Maxson; Sara C Meyer
Journal:  Curr Oncol       Date:  2022-02-01       Impact factor: 3.109

5.  Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies.

Authors:  Amy M Trottier; Lawrence J Druhan; Ira L Kraft; Amanda Lance; Simone Feurstein; Maria Helgeson; Jeremy P Segal; Soma Das; Belinda R Avalos; Lucy A Godley
Journal:  Blood Adv       Date:  2020-10-27

6.  Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.

Authors:  Haijiao Zhang; Yusuke Nakauchi; Thomas Köhnke; Melissa Stafford; Daniel Bottomly; Rozario Thomas; Beth Wilmot; Shannon K McWeeney; Ravindra Majeti; Jeffrey W Tyner
Journal:  Nat Cancer       Date:  2020-08-18

Review 7.  Current Management of Chronic Neutrophilic Leukemia.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

8.  Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.

Authors:  Diletta Fontana; Daniele Ramazzotti; Andrea Aroldi; Sara Redaelli; Vera Magistroni; Alessandra Pirola; Antonio Niro; Luca Massimino; Cristina Mastini; Virginia Brambilla; Silvia Bombelli; Silvia Bungaro; Alessandro Morotti; Delphine Rea; Fabio Stagno; Bruno Martino; Leonardo Campiotti; Giovanni Caocci; Emilio Usala; Michele Merli; Francesco Onida; Marco Bregni; Elena Maria Elli; Monica Fumagalli; Fabio Ciceri; Roberto A Perego; Fabio Pagni; Luca Mologni; Rocco Piazza; Carlo Gambacorti-Passerini
Journal:  Hemasphere       Date:  2020-11-06

Review 9.  Atypical Chronic Myeloid Leukemia: Where Are We Now?

Authors:  Elena Crisà; Maura Nicolosi; Valentina Ferri; Chiara Favini; Gianluca Gaidano; Andrea Patriarca
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

10.  Leukemia Cell Lines: In Vitro Models for the Study of Chronic Neutrophilic Leukemia.

Authors:  Hans G Drexler; Stefan Nagel; Hilmar Quentmeier
Journal:  Curr Oncol       Date:  2021-05-10       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.